Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

This study is testing a combination of two drugs — niraparib (a PARP inhibitor that targets DNA repair in cancer cells) and ipilimumab (an immunotherapy drug) — as a maintenance treatment for people with metastatic pancreatic cancer whose disease has stabilized or responded to initial platinum-based chemotherapy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with metastatic pancreatic adenocarcinoma (pancreatic cancer that has spread) - You completed 8–12 cycles of first-line platinum-based chemotherapy (such as FOLFIRINOX or NALIRIFOX) with stable or improving disease - You stopped oxaliplatin due to side effects but completed the rest of chemotherapy **You may NOT be eligible if...** - Your cancer progressed during initial chemotherapy - You have not yet received first-line treatment - You have conditions that prevent safe use of these medications (e.g., severe autoimmune disease, poor organ function) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.